Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease

First symptom guides diagnosis and prognosis in neurodegenerative diseases – a retrospective study of autopsy proven cases

(2021) Jonathan Vöglein et al.   EUROPEAN JOURNAL OF NEUROLOGY

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention

(2021) Kevin D. Rynearson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Seizure prevalence in neurodegenerative diseases—a study of autopsy proven cases

(2021) Jonathan Vöglein et al.   EUROPEAN JOURNAL OF NEUROLOGY

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

The case for low-level BACE1 inhibition for the prevention of Alzheimer disease

(2021) Eric McDade et al.   Nature Reviews Neurology

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course

(2020) Jonathan Vöglein et al.   JOURNAL OF NEUROLOGY

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Dementia in Down syndrome: unique insights for Alzheimer disease research

(2019) Ira T. Lott et al.   Nature Reviews Neurology

Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers

(2019) Brian A Gordon et al.   BRAIN

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease

(2019) Jonathan Vöglein et al.   BRAIN

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

(2019) Johannes Levin et al.   LANCET NEUROLOGY

Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report

(2019) Joseph F. Arboleda-Velasquez et al.   NATURE MEDICINE

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

(2018) Brian A Gordon et al.   LANCET NEUROLOGY

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus

(2018) Ben Readhead et al.   NEURON

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

(2018) Yakeel T. Quiroz et al.   JAMA Neurology

The amyloid hypothesis on trial

(2018) Simon Makin   NATURE

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

(2018) Eric McDade et al.   NEUROLOGY

The impact of Aβ and tau on prospective cognitive decline in older individuals

(2018) Reisa A. Sperling et al.   ANNALS OF NEUROLOGY

Seizures as an early symptom of autosomal dominant Alzheimer's disease

(2018) Jonathan Vöglein et al.   NEUROBIOLOGY OF AGING

The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

(2017) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

(2017) Clifford R Jack et al.   LANCET NEUROLOGY

Stop Alzheimer’s before it starts

(2017) Eric McDade et al.   NATURE

Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery

(2017) David A. Bennett   PLOS MEDICINE

Non human primate models for Alzheimer’s disease-related research and drug discovery

(2016) Debby Van Dam et al.   Expert Opinion on Drug Discovery

Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

(2016) Francesco Panza et al.   Immunotherapy

Microbes and Alzheimer’s Disease

(2016) Ruth F. Itzhaki et al.   JOURNAL OF ALZHEIMERS DISEASE

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Early changes in CSF sTREM2 in dominantly inherited Alzheimers disease occur after amyloid deposition and neuronal injury

(2016) M. Suarez-Calvet et al.   Science Translational Medicine

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

CAP—advancing the evaluation of preclinical Alzheimer disease treatments

(2015) Eric M. Reiman et al.   Nature Reviews Neurology

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials

(2015) S. Y. H. Kim et al.   NEUROLOGY

Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)

(2015) Nigel J. Cairns et al.   NEUROPATHOLOGY

A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease

(2015) Joshua D. Grill et al.   Alzheimers Research & Therapy

Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred

(2015) Adam S. Fleisher et al.   JAMA Neurology

Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis

(2014) D. C. Ryman et al.   NEUROLOGY

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

(2013) Jens Wagner et al.   ACTA NEUROPATHOLOGICA

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Impaired default network functional connectivity in autosomal dominant Alzheimer disease

(2013) J. P. Chhatwal et al.   NEUROLOGY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease

(2013) Kevin R. Peters et al.   PROGRESS IN NEUROBIOLOGY

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

(2011) Randall J Bateman et al.   Alzheimers Research & Therapy

Hereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models

(2009) Samir Kumar-Singh   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES